Adlai Nortye. (NASDAQ: ANL) — Company Overview, News & Financial Data
Adlai Nortye is a global biopharmaceutical company focused on innovative oncology treatments to improve patient outcomes.
Adlai Nortye.
Adlai Nortye (NASDAQ:ANL) is a global biopharmaceutical company focused on developing innovative treatments in oncology. With a dedication to pushing the boundaries of science to improve patient outcomes, Adlai Nortye is actively engaged in researching and developing therapies that target various stages of cancer. The company's projects span from early discovery to late-stage development, aiming to bring new solutions to unmet medical needs in the cancer treatment landscape. Operating globally, Adlai Nortye's mission revolves around advancing cancer care through groundbreaking research, strategic collaborations, and effective development of its therapeutic pipeline, striving to offer better, more effective treatments to patients around the world.
Snapshot
Operations
Products and/or services of Adlai Nortye.
- Developing immunotherapies for various cancers, focusing on unmet medical needs.
- Advancement in bi-specific antibodies aimed at enhancing tumor killing efficacy.
- Research on oncolytic virus technology for targeted cancer treatment.
- Innovative personalized cancer vaccines designed for individual patient's tumor profiles.
- Development of small molecule inhibitors to target specific cancer pathways.
- Creating CAR-T cell therapies for solid tumors and hematologic cancers.
Adlai Nortye. executive team
- Yang LuCo- Founder, CEO & Chairman
- Ngai Chiu TsePresident & Head of Research & Development
- Xiaofeng YeChief Financial Officer
- Zhiyong YuVice President of Operations
- Chen YangHead of HR & Administration & Government Affairs
- Christopher LiuHead of Investor Relations & Public Relations
- Donghui YangChairman of the Greater China Region
- Nanhai HeHead of Discovery
Key financials
Reported results for Adlai Nortye. , in USD.
- Market cap
- 662M
- Revenue (TTM)
- 18.1M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.7
- Dividend yield
- —
- Profit margin
- -124.8%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 5M | -35.7M | -35.5M | |
| 0 | -52.9M | -51.9M | |
| 5M | -72.6M | -109.2M | |
| 0 | -67.3M | -58.8M |